フォロー
Amina Zoubeidi
Amina Zoubeidi
University of British Columbia
確認したメール アドレス: prostatecentre.com - ホームページ
タイトル
引用先
引用先
Genomic hallmarks and structural variation in metastatic prostate cancer
DA Quigley, HX Dang, SG Zhao, P Lloyd, R Aggarwal, JJ Alumkal, A Foye, ...
Cell 174 (3), 758-769. e9, 2018
4082018
Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity
A Zoubeidi, A Zardan, E Beraldi, L Fazli, R Sowery, P Rennie, C Nelson, ...
Cancer research 67 (21), 10455-10465, 2007
2782007
PD-L1 is highly expressed in Enzalutamide resistant prostate cancer
JL Bishop, A Sio, A Angeles, ME Roberts, AA Azad, KN Chi, A Zoubeidi
Oncotarget 6 (1), 234, 2015
2372015
The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate CancerBRN2 Is an AR-Suppressed Driver of NEPC
JL Bishop, D Thaper, S Vahid, A Davies, K Ketola, H Kuruma, R Jama, ...
Cancer discovery 7 (1), 54-71, 2017
2352017
Cellular plasticity and the neuroendocrine phenotype in prostate cancer
AH Davies, H Beltran, A Zoubeidi
Nature Reviews Urology 15 (5), 271-286, 2018
2172018
The placental gene PEG10 promotes progression of neuroendocrine prostate cancer
S Akamatsu, AW Wyatt, D Lin, S Lysakowski, F Zhang, S Kim, C Tse, ...
Cell reports 12 (6), 922-936, 2015
1992015
Hsp27 Regulates Epithelial Mesenchymal Transition, Metastasis, and Circulating Tumor Cells in Prostate CancerRole of Hsp27 in EMT and Prostate Cancer Metastasis
M Shiota, JL Bishop, KM Nip, A Zardan, A Takeuchi, T Cordonnier, ...
Cancer research 73 (10), 3109-3119, 2013
1982013
Small heat shock proteins in cancer therapy and prognosis
A Zoubeidi, M Gleave
The international journal of biochemistry & cell biology 44 (10), 1646-1656, 2012
1962012
Risk SNP-mediated promoter-enhancer switching drives prostate cancer through lncRNA PCAT19
JT Hua, M Ahmed, H Guo, Y Zhang, S Chen, F Soares, J Lu, S Zhou, ...
Cell 174 (3), 564-575. e18, 2018
1932018
From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer
AV Lapuk, C Wu, AW Wyatt, A McPherson, BJ McConeghy, S Brahmbhatt, ...
The Journal of pathology 227 (3), 286-297, 2012
1852012
Targeting the Cytoprotective Chaperone, Clusterin, for Treatment of Advanced CancerTargeting Clusterin in Cancer
A Zoubeidi, K Chi, M Gleave
Clinical Cancer Research 16 (4), 1088-1093, 2010
1582010
Clusterin mediates TGF-β–induced epithelial–mesenchymal transition and metastasis via Twist1 in prostate cancer cells
M Shiota, A Zardan, A Takeuchi, M Kumano, E Beraldi, S Naito, ...
Cancer research 72 (20), 5261-5272, 2012
1492012
Clusterin knockdown using the antisense oligonucleotide OGX‐011 re‐sensitizes docetaxel‐refractory prostate cancer PC‐3 cells to chemotherapy
RD Sowery, BA Hadaschik, AI So, A Zoubeidi, L Fazli, A Hurtado‐Coll, ...
BJU international 102 (3), 389-397, 2008
1422008
Clusterin Facilitates COMMD1 and I-κB Degradation to Enhance NF-κB Activity in Prostate Cancer CellsClusterin Activates the NF-κB Pathway
A Zoubeidi, S Ettinger, E Beraldi, B Hadaschik, A Zardan, LWJ Klomp, ...
Molecular Cancer Research 8 (1), 119-130, 2010
1392010
The Role of Lineage Plasticity in Prostate Cancer Therapy ResistanceLineage Plasticity in Prostate Cancer Resistance
H Beltran, A Hruszkewycz, HI Scher, J Hildesheim, J Isaacs, EY Yu, ...
Clinical cancer research 25 (23), 6916-6924, 2019
1342019
Targeting the PI3K/Akt pathway in prostate cancer: challenges and opportunities
P Toren, A Zoubeidi
International journal of oncology 45 (5), 1793-1801, 2014
1332014
Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer Progression In VivoTargeting AKT Pathway and AR …
C Thomas, F Lamoureux, C Crafter, BR Davies, E Beraldi, L Fazli, S Kim, ...
Molecular cancer therapeutics 12 (11), 2342-2355, 2013
1272013
The multifaceted roles of STAT3 signaling in the progression of prostate cancer
JL Bishop, D Thaper, A Zoubeidi
Cancers 6 (2), 829-859, 2014
1162014
Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell GrowthTargeting AR in ENZ …
Y Yamamoto, Y Loriot, E Beraldi, F Zhang, AW Wyatt, NA Nakouzi, F Mo, ...
Clinical cancer research 21 (7), 1675-1687, 2015
1082015
A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth In Vitro and In VivoEfficacy of Compound 30 in MDV3100-Resistant …
H Kuruma, H Matsumoto, M Shiota, J Bishop, F Lamoureux, C Thomas, ...
Molecular cancer therapeutics 12 (5), 567-576, 2013
1082013
現在システムで処理を実行できません。しばらくしてからもう一度お試しください。
論文 1–20